Search
Ritlecitinib
go.drugbank.com/drugs/DB14924ApprovedInvestigationalRitlecitinib (PF-06651600) is a highly selective inhibitor of Janus kinase 3 (JAK3) and the tyrosine kinase expressed in hepatocellular carcinoma (TEC) kinase family. In June 2023, it was approved by the FDA for the treatment of severe a...
Zonampanel anhydrous
go.drugbank.com/drugs/DB20448InvestigationalZonampanel anhydrous is under investigation in clinical trial NCT00044070 (A Study to Evaluate the Effects of YM872 on Stroke Lesion Volume in Acute Stroke Patients).
SR-9009
go.drugbank.com/drugs/DB14013ExperimentalSR-9011 has been demonstrated that it is specifically lethal to cancer cells and oncogene-induced senescent cells, including melanocytic naevi, and has no effect on the viability of normal cells or tissues
AME-527
go.drugbank.com/drugs/DB05879ExperimentalAME-527 was generated by protein engineering and identified from a library of antibody variants based on its improved binding properties.
TAK-428
go.drugbank.com/drugs/DB05499ExperimentalIt is based on the novel concept that peripheral nervous tissue that was damaged by diabetes can be repaired and regenerated by stimulating an increase in neurotrophic factors.
Dicoumarol
go.drugbank.com/drugs/DB00266ApprovedDicoumarol is an oral anticoagulant agent that works by interfering with the metabolism of vitamin K. In addition to its clinical use, it is also used in biochemical experiments as an inhibitor of reductases.
Demecarium
go.drugbank.com/drugs/DB00944ApprovedDemecarium is an indirect-acting parasympathomimetic agent that is used to treat glaucoma. It is a cholinesterase inhibitor or an anticholinesterase. Cholinesterase inhibitors prolong the effect of acetylcholine, which is released at the...
Synonyms: Demecarium ionPRLX 93936
go.drugbank.com/drugs/DB06098InvestigationalPRLX 93936 is selectively toxic to cancer cells.
Fulzerasib
go.drugbank.com/drugs/DB21609InvestigationalNCT06936644 (A Multicenter, Single-arm Phase II Study to Evaluate the Efficacy and Safety of Fulzerasib (IBI351) in Combination With Ivonescimab (AK-112) in First-line Treatment of Advanced or Metastatic Non-small
Andexanet alfa
go.drugbank.com/drugs/DB14562ApprovedIt also prevents andexanet alfa from taking up space on phospholipid surface membranes, so that native FXa may bind and assemble the prothrominase complex [A35558]. … However, the effectiveness of andexanet alfa on treating bleeding related to any FXa inhibitors other than apixaban and rivaroxaban was not demonstrated, thus such use is limited [L3725].